金城醫藥(300233.SZ)子公司擬斥1億元設立金城醫藥研究院
格隆匯 9 月 29日丨金城醫藥(300233.SZ)公佈,公司全資子公司北京金城方略醫藥科技有限公司(“金城方略”),擬出資1億元對外投資設立全資子公司山東金城醫藥研究院有限公司(暫定名,最終以工商行政管理部門核准的名稱為準,“金城醫藥研究院”)。
金城方略投資設立金城醫藥研究院,是從公司整體發展戰略出發,旨在打造擁有產業鏈優勢的特色原料藥、高端仿製藥、改良型新藥、創新藥的醫藥技術創新平台,在抗感染、抗病毒、婦科等領域培育具有行業知名的核心技術及優質產品,提升企業綜合競爭力。同時,通過整合內外部優質研發資源,將金城醫藥研究院建設成為國內一流、國際領先的新型藥物研發中心。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.